Accendra Sets Dec 1 Vote on 1-for-20 to 1-for-30 Reverse Split to Cure NYSE Price Deficit

summarizeSummary

Accendra Health's definitive proxy asks shareholders to approve a 1-for-20 to 1-for-30 reverse stock split at a December 1, 2026 special meeting, the company's chosen route to regain NYSE compliance after its stock fell below $1.00.

check_boxKey Events · Corporate Governance and Compliance · ACH

• Reverse Split Vote Set for December 1

  A special meeting on December 1, 2026 asks holders to approve a reverse split at a ratio between 1-for-20 and 1-for-30, with the final ratio left to the Board. A second proposal would adjourn the meeting to solicit more proxies if approval falls short.

• NYSE Minimum Price Deficiency Drives the Vote

  Accendra received NYSE notice on October 6, 2026 that its average closing price was below $1.00 over 30 trading days, and told the exchange on October 14, 2026 it would pursue a reverse split. Failure to implement it leads to delisting proceedings.

• Share Count and Authorized Cap Shrink Proportionally

  At a 1-for-25 ratio, the 76,965,322 shares outstanding as of the October 27, 2026 record date would become about 3,078,612 shares, and authorized common stock would fall from 200,000,000 to 8,000,000. At 1-for-20 the counts are 3,848,266 issued and 10,000,000 authorized; at 1-for-30, 2,565,510 and 6,666,666.

• Majority-of-Outstanding Threshold Raises Turnout Risk

  Approval needs the affirmative vote of a majority of all outstanding shares, so abstentions count as votes against. Coliseum Capital Management holds 13,100,807 shares, or 17.02%, per the proxy's ownership table.

auto_awesomeAnalysis · ACH · Trade & Services

The definitive proxy puts Accendra's NYSE listing on the line. With the stock at $0.233 against the exchange's $1.00 minimum, the company told the NYSE on October 14, 2026 that it intends to cure the deficiency through a reverse split. Because approval requires a majority of all 76,965,322 outstanding shares rather than just those voting, low turnout can sink the measure. Should the split fail to be implemented, the NYSE begins delisting proceedings, pushing the shares to OTC quotation, widening spreads and making the equity financing the company needs harder to raise. Ownership percentages and market value are unchanged by the split itself, but authorized shares are cut in proportion, shrinking future share-issuance capacity.